Abstract
The development of a sensitive, specific, and non-invasive approach for cancer detection will facilitate early detection and, hence, improve the outcome of individuals with known cancer predispositions. Proteomic profiling of blood emerges to be a logical choice of such non-invasive or minimal invasive detection. However, plasma biomarker discovery of pediatric cancers lags behind that of adult cancers, suggesting more efforts are needed in this area. In this study, we used surface-enhanced laser desorption/ionization-time of flight mass spectrometry to profile plasma proteome in osteosarcoma patients. Osteosarcoma is a bone cancer that affects many children and young adults. We have shown that the plasma proteome contains a unique cancer signature that can distinguish patients with osteosarcoma from those with a benign bone disease. To improve cancer biomarker discovery in plasma, we have also shown that depletion of two highly abundant plasma proteins increases the detection sensitivity of lower-abundance proteins. The combination of depletion and proteomic profiling may increase the chance of identifying tumor-derived proteins within the plasma of pediatric cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dahlin DC, Unni K. Bone Tumors: General Aspects and Data on 8542 Cases. 4th ed. Springfield, IL: Charles C. Thomas; 1986.
Huvos A. Bone Tumors: Diagnosis, Treatment and Prognosis. 2nd ed. Philadelphia: WB Saunders; 1991.
Matsunaga E. Hereditary retinoblastoma: host resistance and second primary tumors. J Natl Cancer Inst 1980; 65(1):47–51.
Wang LL, Gannavarapu A, Kozinetz CA et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 2003; 95(9):669–674.
Li Y, Dang TA, Shen J et al. Identification of a plasma proteomic signature to distinguish Âpediatric osteosarcoma from benign osteochondroma. Proteomics 2006; 6(11): 3426–3435.
Jin S, Shen J-N, Guo Q-C et al. 2-D DIGE and MALDI-TOF-MS analysis of the serum proteome in human osteosarcoma. Proteomics Clin Appl 2007; 1:272–285.
Kovacevic A, Hammer A, Stadelmeyer E et al. Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines. J Cell Biochem 2008; 103(3):994–1004.
Saeed AI, Bhagabati NK, Braisted JC et al. TM4 microarray software suite. Methods Enzymol 2006; 411:134–193.
Acknowledgments
We are indebted to Drs. Ching C. Lau, John Hicks, Murali Chintagumpala at the Texas Children’s Cancer Center for their help and support. We would also like to thank Jianhe Shen for her technical support for the study and Carolyn Pena for her assistance in preparing the manuscript. This work was supported by funding from the Carl C. Anderson, Sr. and Marie Jo Anderson Charitable Foundation and the NIH-CA81465.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Li, Y., Dang, T.A., Man, TK. (2012). Plasma Proteomic Profiling of Pediatric Osteosarcoma. In: Clarke, C., McCarthy, D. (eds) SELDI-TOF Mass Spectrometry. Methods in Molecular Biology, vol 818. Springer, New York, NY. https://doi.org/10.1007/978-1-61779-418-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-61779-418-6_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-61779-417-9
Online ISBN: 978-1-61779-418-6
eBook Packages: Springer Protocols